Company Description
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens.
The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics.
It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas.
It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies.
It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC.
Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
| Country | United States |
| IPO Date | Jun 30, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | James F. Parslow |
Contact Details
Address: 40 Speen Street Framingham, Massachusetts United States | |
| Website | https://www.xeneticbio.com |
Stock Details
| Ticker Symbol | XBIO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001534525 |
| CUSIP Number | 984015503 |
| ISIN Number | US9840156023 |
| Employer ID | 45-2952962 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| James F. Parslow | Chief Financial Officer, Chief Operating Officer, Interim Chief Executive Officer & Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 13, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 07, 2024 | 8-K | Current Report |
| Oct 31, 2024 | 8-K | Current Report |
| Oct 31, 2024 | ARS | Filing |
| Oct 31, 2024 | DEFA14A | Filing |
| Oct 31, 2024 | DEF 14A | Filing |
| Oct 21, 2024 | S-3 | Filing |
| Aug 14, 2024 | 8-K | Current Report |
| Aug 13, 2024 | 10-Q | Quarterly Report |